150 related articles for article (PubMed ID: 23679955)
1. Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
Rempel V; Volz N; Gläser F; Nieger M; Bräse S; Müller CE
J Med Chem; 2013 Jun; 56(11):4798-810. PubMed ID: 23679955
[TBL] [Abstract][Full Text] [Related]
2. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
Rempel V; Volz N; Hinz S; Karcz T; Meliciani I; Nieger M; Wenzel W; Bräse S; Müller CE
J Med Chem; 2012 Sep; 55(18):7967-77. PubMed ID: 22916707
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.
Schoeder CT; Kaleta M; Mahardhika AB; Olejarz-Maciej A; Łażewska D; Kieć-Kononowicz K; Müller CE
Eur J Med Chem; 2018 Jul; 155():381-397. PubMed ID: 29902723
[TBL] [Abstract][Full Text] [Related]
4. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells.
Oka S; Kimura S; Toshida T; Ota R; Yamashita A; Sugiura T
J Biochem; 2010 May; 147(5):671-8. PubMed ID: 20051382
[TBL] [Abstract][Full Text] [Related]
6. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
Behrenswerth A; Volz N; Toräng J; Hinz S; Bräse S; Müller CE
Bioorg Med Chem; 2009 Apr; 17(7):2842-51. PubMed ID: 19278853
[TBL] [Abstract][Full Text] [Related]
8. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
Anavi-Goffer S; Irving AJ; Ross RA
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology.
Morales P; Whyte LS; Chicharro R; Gómez-Cañas M; Pazos MR; Goya P; Irving AJ; Fernández-Ruiz J; Ross RA; Jagerovic N
J Med Chem; 2016 Mar; 59(5):1840-53. PubMed ID: 26789378
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and SAR evaluation of coumarin derivatives as potent cannabinoid receptor agonists.
Mohr F; Hurrle T; Burggraaff L; Langer L; Bemelmans MP; Knab M; Nieger M; van Westen GJP; Heitman LH; Bräse S
Eur J Med Chem; 2021 Aug; 220():113354. PubMed ID: 33915369
[TBL] [Abstract][Full Text] [Related]
11. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands.
Kotsikorou E; Sharir H; Shore DM; Hurst DP; Lynch DL; Madrigal KE; Heynen-Genel S; Milan LB; Chung TD; Seltzman HH; Bai Y; Caron MG; Barak LS; Croatt MP; Abood ME; Reggio PH
Biochemistry; 2013 Dec; 52(52):9456-69. PubMed ID: 24274581
[TBL] [Abstract][Full Text] [Related]
12. Identification of GPR55 as a lysophosphatidylinositol receptor.
Oka S; Nakajima K; Yamashita A; Kishimoto S; Sugiura T
Biochem Biophys Res Commun; 2007 Nov; 362(4):928-34. PubMed ID: 17765871
[TBL] [Abstract][Full Text] [Related]
13. Potent, Selective Agonists for the Cannabinoid-like Orphan G Protein-Coupled Receptor GPR18: A Promising Drug Target for Cancer and Immunity.
Mahardhika AB; Załuski M; Schoeder CT; Boshta NM; Schabikowski J; Perri F; Łażewska D; Neumann A; Kremers S; Oneto A; Ressemann A; Latacz G; Namasivayam V; Kieć-Kononowicz K; Müller CE
J Med Chem; 2024 Jun; 67(12):9896-9926. PubMed ID: 38885438
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist.
Brown AJ; Daniels DA; Kassim M; Brown S; Haslam CP; Terrell VR; Brown J; Nichols PL; Staton PC; Wise A; Dowell SJ
J Pharmacol Exp Ther; 2011 Apr; 337(1):236-46. PubMed ID: 21233197
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
Sharir H; Abood ME
Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
[TBL] [Abstract][Full Text] [Related]
16. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
Andrews G; Jones C; Wreggett KA
Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
[TBL] [Abstract][Full Text] [Related]
17. Differential changes in GPR55 during microglial cell activation.
Pietr M; Kozela E; Levy R; Rimmerman N; Lin YH; Stella N; Vogel Z; Juknat A
FEBS Lett; 2009 Jun; 583(12):2071-6. PubMed ID: 19464294
[TBL] [Abstract][Full Text] [Related]
18. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.
Balenga NA; Martínez-Pinilla E; Kargl J; Schröder R; Peinhaupt M; Platzer W; Bálint Z; Zamarbide M; Dopeso-Reyes IG; Ricobaraza A; Pérez-Ortiz JM; Kostenis E; Waldhoer M; Heinemann A; Franco R
Br J Pharmacol; 2014 Dec; 171(23):5387-406. PubMed ID: 25048571
[TBL] [Abstract][Full Text] [Related]
19. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors.
Zhao P; Abood ME
Life Sci; 2013 Mar; 92(8-9):453-7. PubMed ID: 22820167
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
